LCQ-908DGAT1 inhibitor CAS# 956136-95-1 |
- BV6
Catalog No.:BCC5372
CAS No.:1001600-56-1
- Birinapant (TL32711)
Catalog No.:BCC2250
CAS No.:1260251-31-7
- UC 112
Catalog No.:BCC8042
CAS No.:383392-66-3
- Embelin
Catalog No.:BCN2678
CAS No.:550-24-3
- GDC-0152
Catalog No.:BCC2252
CAS No.:873652-48-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 956136-95-1 | SDF | Download SDF |
| PubChem ID | 53387035 | Appearance | Powder |
| Formula | C25H24F3N3O2 | M.Wt | 455.47 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Pradigastat | ||
| Solubility | DMSO : 16.67 mg/mL (36.60 mM; ultrasonic and warming and heat to 60°C) H2O : < 0.1 mg/mL (insoluble) H2O : < 0.1 mg/mL (insoluble) | ||
| Chemical Name | 2-[4-[4-[5-[[6-(trifluoromethyl)pyridin-3-yl]amino]pyridin-2-yl]phenyl]cyclohexyl]acetic acid | ||
| SMILES | C1CC(CCC1CC(=O)O)C2=CC=C(C=C2)C3=NC=C(C=C3)NC4=CN=C(C=C4)C(F)(F)F | ||
| Standard InChIKey | GXALXAKNHIROPE-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C25H24F3N3O2/c26-25(27,28)23-12-10-21(15-30-23)31-20-9-11-22(29-14-20)19-7-5-18(6-8-19)17-3-1-16(2-4-17)13-24(32)33/h5-12,14-17,31H,1-4,13H2,(H,32,33) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | LCQ-908 is a new generation of diacylglycerol acyltransferase 1 (DGAT1) inhibitor as anti-obesity and anti-diabetic agents.In Vivo:LCQ-908 is a potent inhibitor of DGAT1, and has been used for the phase II clinical trials to treat diabetes and obesity[1]. References: | |||||
LCQ-908 Dilution Calculator
LCQ-908 Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.1955 mL | 10.9777 mL | 21.9553 mL | 43.9107 mL | 54.8884 mL |
| 5 mM | 0.4391 mL | 2.1955 mL | 4.3911 mL | 8.7821 mL | 10.9777 mL |
| 10 mM | 0.2196 mL | 1.0978 mL | 2.1955 mL | 4.3911 mL | 5.4888 mL |
| 50 mM | 0.0439 mL | 0.2196 mL | 0.4391 mL | 0.8782 mL | 1.0978 mL |
| 100 mM | 0.022 mL | 0.1098 mL | 0.2196 mL | 0.4391 mL | 0.5489 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 5 μM for BCRP-mediated efflux activity
LCQ908 is a diacylglycerol acyltransferase-1 (DGAT-1) inhibitor. DGAT-1 has been recognized to catalyze the final committed step of processing dietary fatty acids into triglycerides carried on chylomicrons for transport around the body. Thus,inhibition of DGAT-1 represents a novel approach to treat metabolic disease.
In vitro: In vitro studies suggest that glucuronidation is the predominant metabolism pathway for elimination of LCQ908 in humans. LCQ908 inhibited BCRP-mediated efflux activity in a dose-dependent fashion with an IC50 value of 5 μM. LCQ908 also inhibited OATP1B1, OATP1B3, and OAT3 activity in a concentration-dependent manner with estimated IC50 values of 1.66 ± 0.95 μM, 3.34 ± 0.64 μM, and 0.973 ± 0.11 μM, respectively [1].
In vivo: LCQ908 was fond to suppress the postprandial triglyceride levels in rats, dogs as well as monkeys. In rats whose LPL activity had been abolished, LCQ908 reduced the postprandial accumulation of plasma triglyceride. Additional, LCQ908 decreased the postprandial rate of CM-TG secretion into the lymphatic duct and reduced the size of CMs [2].
Clinical trial: In a clinical trial, LCQ908 was found to be able to lower fasting triglyceride levels in familial chylomicronemia syndrome patients maintained on a very low-fat diet, and represents a potential drug treatment for this orphan disease [3].
References:
[1] Kulmatycki K,Hanna I,Meyers D,Salunke A,Movva A,Majumdar T,Natrillo A,Vapurcuyan A,Rebello S,Sunkara G,Chen JEvaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor. Int J Clin Pharmacol Ther.2015 May;53(5):345-55.
[2] Meyers CD, Serrano-Wu M, Amer A, Chen J, Eric R, Commerford R, et al. The DGAT1 inhibitor pradigastat decreases chylomicron secretion and prevents postprandial triglyceride elevation in humans [abstract]J Clin Lipidol.2013;7:285.
[3] Charles Meyers, Daniel Gaudet, Karine Tremblay, Ahmed Amer, Jin Chen, Feng Aimin. The DGAT1 Inhibitor LCQ908 decreases triglyceride levels in patients with the familial chylomicronemia syndrome. Journal of Clinical Lipidology, Vol 6, No 3, June 2012, 266-267.
- ARN-509
Catalog No.:BCC3724
CAS No.:956104-40-8
- Cochinchinenin C
Catalog No.:BCN5329
CAS No.:956103-79-0
- (2R)-8-Methylsocotrin-4'-ol
Catalog No.:BCN3737
CAS No.:956103-75-6
- NS 11021
Catalog No.:BCC6290
CAS No.:956014-19-0
- PI-3065
Catalog No.:BCC5379
CAS No.:955977-50-1
- MK-1775
Catalog No.:BCC2543
CAS No.:955365-80-7
- 8,3'-Diprenylapigenin
Catalog No.:BCN6482
CAS No.:955135-37-2
- 10Panx
Catalog No.:BCC1245
CAS No.:955091-53-9
- 5-Hydroxy-7-acetoxy-8-methoxyflavone
Catalog No.:BCN4506
CAS No.:95480-80-1
- Hydroxytuberosone
Catalog No.:BCN4552
CAS No.:95456-43-2
- Neotuberostemonone
Catalog No.:BCN4505
CAS No.:954379-68-1
- 15-Hydroxy-7-oxodehydroabietic acid
Catalog No.:BCN4504
CAS No.:95416-25-4
- TCS HDAC6 20b
Catalog No.:BCC2427
CAS No.:956154-63-5
- mavatrep
Catalog No.:BCC6457
CAS No.:956274-94-5
- Phoyunnanin C
Catalog No.:BCN3686
CAS No.:956344-38-0
- Ranolazine
Catalog No.:BCC3847
CAS No.:95635-55-5
- Ranolazine 2HCl
Catalog No.:BCC2503
CAS No.:95635-56-6
- Demethylsonchifolin
Catalog No.:BCN4551
CAS No.:956384-55-7
- UNBS 5162
Catalog No.:BCC4008
CAS No.:956590-23-1
- MM-22
Catalog No.:BCC6114
CAS No.:956605-71-3
- LDE225 (NVP-LDE225,Erismodegib)
Catalog No.:BCC5066
CAS No.:956697-53-3
- 8beta,9alpha-Dihydroxylindan-4(5),7(11)-dien-8alpha,12-olide
Catalog No.:BCN8024
CAS No.:956707-04-3
- Euscaphin B
Catalog No.:BCN4507
CAS No.:956869-95-7
- Betamethasone hydrochloride
Catalog No.:BCC4256
CAS No.:956901-32-9
DGAT1 inhibitors as anti-obesity and anti-diabetic agents.[Pubmed:20597032]
Curr Opin Drug Discov Devel. 2010 Jul;13(4):489-96.
Since 2008, significant advances have been made in understanding the role of diacylglycerol acyl transferase-1 (DGAT1) in disease states such as diabetes and obesity. Gene deletion and overexpression studies have provided important new insights into the function of DGAT1, as have the first reports from preclinical models of small-molecule inhibitor effects, which are discussed in this review in relation to the phenotypes of DGAT knockout and overexpression models. The progress of medicinal chemistry efforts has resulted in a new generation of DGAT1 inhibitors that have progressed into clinical development, with the leading compound LCQ-908 (Novartis AG) now in phase II clinical trials. This exciting progress has led researchers to anticipate that an understanding of the human pharmacology of DGAT1 inhibitors, as well as their potential as therapeutic agents for the treatment of diabetes and obesity, will be achieved in the next few years.
